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 The diffi culty in determining the mechanisms of neurodegenera-
tive disease is confounded by a poor understanding of the normal 
functions of the proteins implicated in disease. The relationship 
between the normal and toxic activities of proteins such as 
  -synuclein in Parkinson ’ s disease or Tau and amyloid precursor 
protein in Alzheimer ’ s disease is gaining attention ( Gitler and 
Shorter, 2007 ). Prion diseases are caused by misfolding of PrP, a 
conserved glycoprotein tethered to cell membranes by a glycosyl-
phosphatidylinositol anchor ( Prusiner, 1998 ). Highly expressed 
in neurons, PrP is also present in many other cell types ( Aguzzi 
and Heikenwalder, 2006 ). However, neurons are the only cells 
thought to be adversely affected by the misfolding of PrP during 
prion diseases, which range from Creutzfeldt-Jakob disease and 
fatal familial insomnia in humans to bovine spongiform encepha-
lopathy and chronic wasting disease in ruminants. Despite recent 
major advances into the structure, detection, and amplifi cation of 
prions (for review see  Caughey and Baron, 2006 ), the pathway 
of prion-mediated neurodegeneration remains to be understood. 
Several investigators suggest that the study of PrP ’ s normal func-
tion may shed light on the pathogenic sequelae of prion disease 
(for reviews see  Caughey and Baron, 2006 ;  Steele et al., 2007a ). 
The normal function of the prion protein (PrP) — the caus-
ative agent of mad cow or prion disease — has long re-
mained out of reach. Deciphering PrP ’ s function may help 
to unravel the complex chain of events triggered by PrP 
misfolding during prion disease. In this issue of the JCB, 
an exciting paper (Khosravani, H., Y. Zhang, S. Tsutsui, 
S. Hameed, C. Altier, J. Hamid, L. Chen, M. Villemaire, 
Z. Ali, F.R. Jirik, and G.W. Zamponi. 2008.  J. Cell Biol . 
181:551 – 565) connects diverse observations regard-
ing PrP into a coherent framework whereby PrP dampens 
the activity of an  N -methyl- D -aspartate (NMDA) receptor 
(NMDAR) subtype and reduces excitotoxic lesions. The 
fi ndings of this study suggest that understanding the nor-
mal function of proteins associated with neurodegenera-
tive disease may elucidate the molecular pathogenesis.
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 The study of the normal function of PrP has been ham-
pered by one simple fact revealed in 1992 in a seminal study 
from Charles Weissmann’s laboratory ( Bueler et al., 1992 ): the 
PrP knockout mouse has no overt phenotype (nor, for that mat-
ter, does the PrP-null cow [ Richt et al., 2006] ). However, sub-
sequent studies have uncovered a multitude of phenotypes in 
PrP knockout mice, many of which manifest upon physiological 
challenge (for review see  Steele et al., 2007a ). These pheno-
types range from defects in stem cell maintenance ( Steele et al., 
2006; Zhang et al., 2006 ) to dental abnormalities ( Schneider 
et al., 2007 ) to enhanced susceptibility to ischemia ( McLennan 
et al., 2004 ) and seizure ( Walz et al., 1999 ) and even resistance 
to viral infection ( Thackray and Bujdoso, 2002 ). Because of the 
diverse cellular functions attributed to PrP, molecular character-
ization of the phenotypes of PrP knockout mice is sorely needed, 
and Khosravani et al. (see p.  551 of this issue) seize the torch. 
By using electrophysiology, pharmacology, cell death assays, 
and biochemistry, they reveal a new and exciting role for PrP in 
directly silencing NMDARs ( Khosravani et al., 2008 ). 
 Khosravani et al. (2008) launch their investigation by re-
visiting the peculiar electrophysiological properties of PrP-null 
neurons, which were fi rst documented more than a decade ago 
( Collinge et al., 1994 ). Using hippocampal slices, they observed 
increased action potentials and a lower stimulation threshold to 
induce action potentials in PrP knockouts. Next, the authors fi nd 
that the NMDAR antagonist aminophosphonovaleric acid res-
cues the effect of PrP deletion on NMDAR excitation, pointing 
toward NMDARs as key mediators of this hyperexcitability pheno-
type. NMDARs are a subclass of ligand-gated excitatory gluta-
mate receptors that control fast synaptic transmission. Because 
they are calcium permeable (in addition to sodium), NMDARs 
have key roles in mediating constructive events like plasticity 
involved in learning but also participate in destructive events 
such as damage after stroke ( Villmann and Becker, 2007 ). 
 Further slice recording experiments by  Khosravani et al. 
(2008) revealed that in the absence of magnesium, which blocks 
NMDARs at resting potential, PrP-null neurons show an exag-
gerated hyperexcitability, reaching a seizurelike state much more 
rapidly than control slices. Next, the authors measure miniature 
excitatory postsynaptic currents in dissociated cultures of hippo-
campal neurons. Compared with controls, PrP-null neurons 
exhibited currents that had larger amplitudes and lasted much 
longer in response to the focal application of NMDA. Impor-
tantly, the authors performed additional control experiments to 
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 How do these new fi ndings relate to prion diseases? Clearly, 
the detection of exaggerated NMDAR activity in prion-diseased 
samples would be a smoking gun implicating a loss of PrP 
function in prion disease. Do the familial mutants of PrP fail 
to effectively silence NMDARs, leading to hyperexcitability 
and a mechanism of neuronal damage similar to excitotoxicity? 
The cell death pathways involved in prion disease are far 
from understood ( Steele et al., 2007b ), and this new angle of 
investigation deserves attention, as perhaps NMDAR inhibition 
will have potential as a prion disease therapeutic strategy. 
Based on an interaction of PrP with NMDARs, one might 
speculate that the psychiatric symptoms of prion diseases could 
relate to defects in glutamatergic neurotransmission brought 
about either by PrP being titrated away from NR2D subunits 
or from direct interference by PrP oligomers or aggregates 
with NMDARs. 
 How does PrP silence NMDAR? As noted by  Khosravani 
et al. (2008) , PrP could block agonist binding, stabilize the 
closed state of the channel, or indirectly regulate function by 
interfering with signaling pathways affecting NR2D-containing 
NMDARs. With respect to NMDAR assembly, very little is known 
about NR2D subunits other than that they likely require NR1 
subunits to reach the cell surface. In wild-type conditions, with 
ample PrP present on the neuronal cell surface, these channels 
will not open. What is the molecular logic of building a toni-
cally inhibited NMDAR? Perhaps these channels only respond 
to extreme stimuli where they need not only a magnesium un-
blocking event but also a PrP-releasing event to open. The iden-
tifi cation and characterization of additional interacting partners 
of PrP or NMDARs will be a complex and stimulating area of 
research. These questions aside, it is exciting to see the pieces 
of the PrP function puzzle start to come together. 
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rule out potential artifacts caused by the use of PrP knockout neu-
rons derived from a mouse strain of mixed genetic background 
by (1) using siRNAs to knock down PrP and (2) by reconstituting 
PrP into PrP-null neurons. To address the question of how PrP 
infl uences the NMDAR,  Khosravani et al. (2008) go on to deter-
mine that PrP may interact directly with the NR2D subunit 
of NMDAR ( Fig. 1 ) by demonstrating that PrP colocalizes with 
NR2D on the neuronal surface by immunofl uoresence micros-
copy and that the two proteins can coimmunoprecipitate. 
 The next thrust of this story links PrP deletion to neuro-
toxicity mediated by excessive excitatory amino acid exposure, 
or excitotoxicity. Brief exposures of cultured neurons to NMDA 
lead to a marked increase in the death of PrP-null neurons com-
pared with controls. The authors also show that in vivo applica-
tion of NMDA directly into the hippocampus causes much larger 
lesions in PrP knockout brains. Thus, PrP protects against direct 
excitotoxic lesions, which provides a mechanistic understanding 
of a previous observation that PrP knockouts have increased 
susceptibility to stroke ( McLennan et al., 2004 ). In conclusion, 
 Khosravani et al. (2008) bridge the gap between PrP dampening 
excessive depolarization events in neurons to an important, bio-
medically relevant phenotype of PrP knockout mice. 
 This work raises many exciting questions about PrP ’ s nor-
mal function, its relation to prion diseases, and the study of 
NMDAR activity. First, how much explanatory power does 
NMDAR inhibition provide in terms of illuminating other 
PrP knockout phenotypes (for reviews see  Sakudo et al., 2006 ; 
 Steele et al., 2007a )? Recent work from another laboratory has 
implicated kainite receptors, a glutamate-responsive ion-gated 
channel subtype, in mediating the enhanced damage of PrP 
knockout neurons in response to seizures ( Rangel et al., 2007 ). 
Further experiments will be required to discern whether the re-
sults of  Khosravani et al. (2008) and this seizure study are di-
rectly or indirectly related. 
 Figure 1.  PrP may directly interact with the NR2D subunit of NMDAR to regulate its activity. (A) In wild-type neurons, PrP silences the NR2D-containing 
NDMAR, preventing depolarization and calcium entry. (B) In PrP-null neurons, the NR2D-containing NMDAR opens much more readily, leading to excessive 
calcium entry and more severe excitotoxic injury during conditions of excessive glutamate release. Magnesium, which blocks NMDAR at resting potential, 
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